MiMedx Group (MDXG) Issues Letter to Shareholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
MIMEDX Mails Letter to Shareholders
May 16, 2022 8:00 AM EDTHighlights Successful Execution of Transformation Strategy Under CEO Tim Wright
Reaffirms Commitment to Enhancing Value for ALL Shareholders
Urges Shareholders to Vote FOR Both of MIMEDXs Highly Qualified Director Nominees James L. Bierman and Phyllis Gardner, M.D. on the WHITE Proxy Card
MARIETTA, Ga., May 16, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (MIMEDX or the Company), a transformational placental biologics company, has mailed a letter to shareholders in connection with its 2022 Annual Meeting of Shareholders scheduled for... More
